Citations 648

P3‐427: MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIA WITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AV‐1451 UPTAKE

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3461

P3‐411: ANALYSIS OF IOFLUPANE‐SPECT FINDINGS USING DATQUANT IN PATIENTS WITH IDIOPATHIC REM SLEEP BEHAVIOR DISORDER

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3445

P3‐364: RATES OF LOBAR ATROPHY IN ASYMPTOMATIC MAPT MUTATION CARRIERS

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3397

P2‐329: TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2019.06.2736

P2‐314: THE MULTIDOMAIN IMPAIRMENT RATING (MIR) SCALE: INITIAL RELIABILITY DATA ON A MULTIDIMENSIONAL SCALE DESIGNED FOR FTLD SPECTRUM DISORDERS

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2019.06.2721

P1‐369: AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2019.06.924

P1‐367: COMPARISON OF IOFLUPANE‐SPECT FINDINGS USING DATQUANT IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA AND DEMENTIA WITH LEWY BODIES

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2019.06.922

Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity

Stroke | September 12, 2019 | Volume: 50 | Issue: 11 | Pages: 3037-3044

10.1161/strokeaha.119.025822 | PMID 31510903

Background and Purpose— White matter hyperintensity (WMH) burden is associated with stroke and cognitive decline. Risk factors associated with the longitudinal progression of WMH in the general population have not been systematically investigated. To investigate the primary midlife and current cardiometabolic risk factors associated with changes in WMH over time in a population cohort. Methods— This cohort study included participants enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study in Olmsted County, Minnesota with at least 2 consecutive WMH assessments on fluid-attenuated inversion recovery-magnetic resonance images (n=554, ≥60 years with midlife assessments) with relevant baseline laboratory measures of interest. Linear mixed model regression was used to determine the important components of cardiometabolic risk profile at baseline that were associated with future progression of WMH. These analyses were controlled for age and sex. Sensitivity analyses were conducted using stratification by sex. The main outcome measure was percent change in WMH normalized to total intracranial volume. Three sets of models were constructed to evaluate individual (1) midlife risk factors, (2) current risk factors including the presence of metabolic syndrome and its constituents, and (3) baseline measurements of continuous laboratory measures of cardiometabolic risk. Results— Age was the strongest predictor of progression in WMH ( P <0.001). Baseline hypertension ( P <0.001), midlife hypertension ( P =0.003), and baseline fasting glucose in males ( P =0.01) were predictive of WMH change. The presence of metabolic syndrome was not associated with progressive WMH. In sensitivity analyses, associations between hypertension and WMH progression were stronger in females. Baseline serum glucose was associated with increase in WMH but was not significant in females in the stratified analysis. Other continuous laboratory measures of vascular risk were not associated with progressive WMH. Conclusions— Midlife and current hypertension in all participants and fasting glucose in males were associated with quantitative changes in white matter. Prospective clinical studies should determine optimal blood pressure to reduce stroke and cognitive impairment during aging.
Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration

Brain | September 4, 2019 | Volume: 142 | Issue: 11 | Pages: 3621-3635

10.1093/brain/awz277 | PMID 31562527

The specific effect of TDP-43 pathology on grey matter volume in individuals without frontotemporal lobar degeneration is unclear. Bejanin et al. reveal a major and independent contribution of TDP-43 to neurodegeneration and shed light on the regional distribution of TDP-43-related atrophy in older adults.
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

Brain | August 28, 2019 | Volume: 142 | Issue: 10 | Pages: 3230-3242

10.1093/brain/awz268 | PMID 31501889

See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.